Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current medicinal chemistry Pub Date : 2025-08-14 DOI:10.2174/0109298673371957250707161319

Hooman Yahyazadeh, Tahereh Farkhondeh, Abolfazl Bagherifard, Karo Khosravi, Reza Ahmadi, Hamed Aramjoo, Babak Roshanravan, Saeed Samarghandian

{"title":"Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.","authors":"Hooman Yahyazadeh, Tahereh Farkhondeh, Abolfazl Bagherifard, Karo Khosravi, Reza Ahmadi, Hamed Aramjoo, Babak Roshanravan, Saeed Samarghandian","doi":"10.2174/0109298673371957250707161319","DOIUrl":null,"url":null,"abstract":"Introduction: One of the most effective osteoanabolic drugs for treating osteoporosis is romosozumab, which was developed as a consequence of growing knowledge of the Wnt signaling system. This review explored how romosozumab affects the bone mineral density (BMD) in osteoporotic patients.Methods: Up until January 2024, PubMed, Web of Science, and Scopus were reviewed for any randomized controlled trials (RCTs) evaluating the impact of osteoporotic treatment with romosozumab on BMD changes and bone metabolism markers in primary osteoporosis patients. Pooled Hedges' g indices, which were consistently used across all included studies to measure standardized mean differences, were computed along with their corresponding 95% confidence intervals using either a random-effects or fixed-effects model.Results: Out of the 1855 papers, 24 RCTs met the inclusion criteria. Patients with osteoporosis who received romosozumab for a period of time demonstrated an augmentation in their lumbar spine BMD. The study findings indicated that the total hip and femoral neck BMD demonstrated significant enhancement in 22 (out of 23) and 19 (out of 21) studies, respectively.Conclusion: In patients with osteoporosis, romosozumab could markedly increase the total hip, lumbar spine, and femoral neck BMD. This finding could be verified by measuring bone turnover indicators such as PINP, TRACP-5b, and CTX.","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673371957250707161319","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: One of the most effective osteoanabolic drugs for treating osteoporosis is romosozumab, which was developed as a consequence of growing knowledge of the Wnt signaling system. This review explored how romosozumab affects the bone mineral density (BMD) in osteoporotic patients.

Methods: Up until January 2024, PubMed, Web of Science, and Scopus were reviewed for any randomized controlled trials (RCTs) evaluating the impact of osteoporotic treatment with romosozumab on BMD changes and bone metabolism markers in primary osteoporosis patients. Pooled Hedges' g indices, which were consistently used across all included studies to measure standardized mean differences, were computed along with their corresponding 95% confidence intervals using either a random-effects or fixed-effects model.

Results: Out of the 1855 papers, 24 RCTs met the inclusion criteria. Patients with osteoporosis who received romosozumab for a period of time demonstrated an augmentation in their lumbar spine BMD. The study findings indicated that the total hip and femoral neck BMD demonstrated significant enhancement in 22 (out of 23) and 19 (out of 21) studies, respectively.

Conclusion: In patients with osteoporosis, romosozumab could markedly increase the total hip, lumbar spine, and femoral neck BMD. This finding could be verified by measuring bone turnover indicators such as PINP, TRACP-5b, and CTX.

查看原文本刊更多论文

Romosozumab对骨质疏松患者骨密度的影响：系统回顾和荟萃分析

引言：治疗骨质疏松症最有效的骨合成代谢药物之一是romosozumab，它是随着Wnt信号系统知识的增长而发展起来的。本综述探讨了romosozumab如何影响骨质疏松症患者的骨矿物质密度（BMD）。方法：截至2024年1月，PubMed、Web of Science和Scopus检索了所有评估romosozumab治疗骨质疏松对原发性骨质疏松患者骨密度变化和骨代谢指标影响的随机对照试验（rct）。在所有纳入的研究中，汇集的对冲指数（Pooled Hedges’s g）一直用于测量标准化平均差异，并使用随机效应或固定效应模型计算其相应的95%置信区间。结果：1855篇论文中，24篇rct符合纳入标准。骨质疏松症患者接受romosozumab治疗一段时间后，其腰椎骨密度有所增加。研究结果表明，23项研究中有22项和21项研究中分别有19项研究表明，全髋关节和股骨颈骨密度显著增强。结论：在骨质疏松症患者中，罗莫索单抗可显著增加髋部、腰椎和股骨颈的骨密度。这一发现可以通过测量骨转换指标如PINP、TRACP-5b和CTX来验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.